| 1.58 0.03 (1.94%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.02 | 1-year : | 2.25 |
| Resists | First : | 1.73 | Second : | 1.92 |
| Pivot price | 1.59  |
|||
| Supports | First : | 1.41 | Second : | 1.18 |
| MAs | MA(5) : | 1.49  |
MA(20) : | 1.59 |
| MA(100) : | 1.66 |
MA(250) : | 1.26 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 21.5 |
D(3) : | 12.4 |
| RSI | RSI(14): 51.2 | |||
| 52-week | High : | 2.5 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ITRM ] has closed above bottom band by 47.1%. Bollinger Bands are 20.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.6 - 1.61 | 1.61 - 1.62 |
| Low: | 1.53 - 1.54 | 1.54 - 1.55 |
| Close: | 1.56 - 1.58 | 1.58 - 1.59 |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Tue, 02 Apr 2024
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript - Yahoo Finance
Mon, 01 Apr 2024
Iterum Therapeutics PLC (ITRM) is higher by 14.29% Monday In Premarket Trading - InvestorsObserver
Thu, 07 Mar 2024
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up - Zacks Investment Research
Wed, 06 Mar 2024
Iterum Therapeutics advances NDA resubmission timeline By Investing.com - Investing.com
Tue, 13 Feb 2024
Should You Hold Iterum Therapeutics PLC (ITRM) Stock Tuesday Morning? - InvestorsObserver
Wed, 07 Feb 2024
Iterum Therapeutics PLC (ITRM) is up 5.70% Wednesday In Premarket Trading - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 7.5 (%) |
| Shares Short | 1,230 (K) |
| Shares Short P.Month | 975 (K) |
| EPS | -2.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.8 % |
| Return on Equity (ttm) | -355.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.54 |
| PEG Ratio | 0 |
| Price to Book value | -3.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|